Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to date...

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing Funding extends Xeltis’ Series D2 financing round to €44.5 million EINDHOVEN, The...